Factor This Power Engineering
Live Events
DTECH⢠Events
POWERGEN®
Calendar
Resource Center
Webinars
Podcasts
White Papers
Contribute Content
Solar
Utility Scale
Community
Residential
Wind Power
Turbines & Equipment
Offshore
Power Grid
Transmission
Outage Management
Grid Modernization
Smart Grids
Microgrids
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Pumped Storage
Long Duration
Business
Policy & Regulation
Project Development
Finance
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Utility Scale
Community
Residential
Wind Power
Turbines & Equipment
Offshore
Power Grid
Transmission
Outage Management
Grid Modernization
Smart Grids
Microgrids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Pumped Storage
Long Duration
Business
Policy & Regulation
Finance
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Resource Center
Webinars
Podcasts
Whitepapers
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Royalty Pharma plc - Class A Ordinary Shares
(NQ:
RPRX
)
39.77
+0.23 (+0.59%)
Streaming Delayed Price
Updated: 11:35 AM EST, Dec 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Royalty Pharma plc - Class A Ordinary Shares
< Previous
1
2
3
4
Next >
Royalty Pharma to Present at Upcoming Investor Conferences
November 26, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Reports Third Quarter 2025 Results
November 05, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
November 04, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Fourth Quarter 2025 Dividend
October 17, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
October 09, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
September 29, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
September 19, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
September 11, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
September 10, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
September 04, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
September 02, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
September 02, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
September 02, 2025
From
Zenas BioPharma
Via
GlobeNewswire
Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million
August 25, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
August 13, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Reports Second Quarter 2025 Results
August 06, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Third Quarter 2025 Dividend
July 18, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
July 17, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
July 16, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
June 24, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
June 04, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Completes the Acquisition of Its External Manager
May 16, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at Upcoming Investor Conferences
May 13, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
May 12, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Reports First Quarter 2025 Results
May 08, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Second Quarter 2025 Dividend
April 21, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025
April 17, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors
April 08, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Upcoming Investor Day
March 27, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference
February 27, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
